The DAPA-HF trial [55] and the EMPEROR-Reduced trial [56] have shown that SGLT-2 inhibitors (dapagliflozin and empagliflozin) reduced the risk of worsening HF events in adults with reduced EF, irrespective of the presence of diabetes at baseline. This evidence concerns the gene SLC5A2 and hydrops fetalis.